This site is my collection of updates, statistics and analysis on intellectual property in Canada. I am a partner at DLA Piper (Canada) LLP practicing in the area of intellectual property (more about me). Material on this website are my own views and do not reflect the position of DLA Piper (Canada) LLP, any of its member firms around the world, or any of its clients. IPPractice.ca grew out of my hobby to gather and share interesting updates on intellectual property to friends and colleagues. Highlights include:

Recent Posts:

Federal Court

The Federal Court has issued a revised COVID-19 order (see earlier post) clarifying the 2-week buffer period after the end of the Suspension Period such that timelines will be begin to run June 30 for the Western and Eastern provinces and on July 14 for Ontario, Quebec and the territories. The update also clarifies the handling of original affidavits that may have been submitted electronically.

Virtual Hearings

On Friday, I’m speaking on an IPIC webinar, “The Virtual IP Court Hearing: What You Should Know Before You “Zoom” Into Court” with Nicole Mantini, Josh Spicer and Andrew Bernstein. I’ll be sharing some of my recent experiences from the two and half-week virtual trial in the Rovi v Videotron proceeding.


Patent Branch has issued a Practice Notice addressing requests to record a transfer, registering document and changing a name under sections 124, 125 and 126 of the Patent Rules and section 49 of the Patent Act.

Foreign Updates

A couple of non-Canadian developments that may be of interest:

  • a majority of the US Supreme Court allowed the registration for the trademark “Booking.com” in the face of arguments that it was generic: “According to the PTO, adding “.com” to a generic term—like adding “Company”—can convey no source-identifying meaning. That premise is faulty, for only one entity can occupy a particular Internet domain name at a time, so a “generic.com” term could convey to consumers an association with a particular website.”
  • the UK Supreme Court in Regeneron Pharmaceuticals Inc v Kymab Ltd considered patent sufficiency: “The disclosure required of the patentee is such as will, coupled with the common general knowledge existing as at the priority date, be sufficient to enable the skilled person to make substantially all the types or embodiments of products within the scope of the claim.”


The Canadian Intellectual Property Office has extended the period of designated days so certain time limits will now be extended until July 20, 2020. While the period of designated days may be extended further, the Patent Branch is offering a webinar on the “end of designated days”.

Canadian Intellectual Property